About this episode
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.Presenters:Angela Weyand, MDAssociate Professor, Pediatric Hematology OncologyCo-Director, Combined Hematology/Gynecology ProgramPediatric Medical Director, Hemophilia Treatment CenterUniversity of Michigan Medical SchoolAnn Arbor, MichiganGuy Young, MDDirector, Hemostasis and Thrombosis CenterDirector, Clinical Coagulation LaboratoryCancer and Blood Disease InstituteChildren's Hospital Los AngelesProfessor of PediatricsDivision of Hematology/OncologyDepartment of PediatricsUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaGet access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
